[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypersensitivity-reactions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypersensitivity-reactions":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100637325","phase-1-novel-biomarkers-of-non-ige-immediate-hypersensitivity-drug-reactions-100637325",false,"NCT07605806","Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions","Inclusion Criteria:\n\n* Male or female age ≥ 18 years.\n* Adequate kidney function as defined by creatinine level within normal institutional limits at the participant's first visit.\n* Women of child bearing potential must agree to a reliable form of highly effective contraception (hormonal, device, or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of vancomycin therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the Principal Investigator and her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent.\n* Ability to clearly understand and speak English at an 8th grade reading level. For safety reasons, participants must speak English due to the anticipated need for clear and timely communication with investigators and the study team in emergency situations, since the investigators and study team are English speaking.\n\nExclusion Criteria:\n\n* Participants who have previously received vancomycin in any formulation, including oral or intravenous.\n* History of allergic reactions to study drug or reactions attributed to compounds of similar chemical or biologic composition to vancomycin, including active product or excipients.\n* Concurrent use of medications thought to cause non-specific mast cell activation (e.g. opioids)\n* Baseline serum tryptase over 8.0 ng\u002FmL and\u002For known mast cell disorder, including, but not limited to, mastocytosis, idiopathic mast cell activation syndrome, and hereditary alpha tryptasemia\n* Active infection or immunodeficiency\n* Unstable cardiovascular disease\n* Renal insufficiency\n* Current hearing deficit\n* Current use of beta-blockers\n* Use of immunomodulatory therapies or oral corticosteroids within the previous 1 month\n* Use of biologics in the previous 6 months, including omalizumab\n* Participants taking antihistamines must stop these drugs for one week prior to enrollment and must refrain from taking antihistamines during the duration of the study so as not to interfere with responses during drug challenge",true,"ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this clinical trial is to investigate biomarkers of non-IgE-mediated immediate hypersensitivity reactions during infusion of intravenous vancomycin. The main question it aims to answer is:\n\n• Identifying novel biomarkers in blood that occur during infusion reaction\n\nParticipants will:\n\n* Have allergy skin testing for vancomycin\n* Receive an infusion of vancomycin",[27,28,29],"Healthy Volunteer","Hypersensitivity Reactions","Vancomycin",[31,32,33],"non-IgE-mediated hypersensitivity reaction","Healthy volunteer","vancomycin","RECRUITING","2026-05-21",{"date":37,"type":38},"2026-05-26","ACTUAL",{"date":35,"type":20},{"date":41,"type":20},"2027-06-30",{"name":43,"class":44},"Johns Hopkins University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100637016","evaluation-of-hypersensitivity-reactions-to-silk-fibroin-versus-2-octyl-cyanoacrylate-mesh-in-shoulder-surgery-100637016","NCT07573202","Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery","Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh a Randomized Controlled Trial to Evaluate Hypersensitivity Reactions in Shoulder Surgery","Inclusion Criteria:\n\n* open shoulder procedure with Dr. James Gregory or Dr. Robert Fullick.\n\nExclusion Criteria:\n\n* Prior documented medical adhesive contact allergy.\n* Negative pressure wound dressings.\n* Any procedure involving a wound problem at the planned surgical site.",{"count":54,"type":20},350,[56],"NA","The purpose of this study is to document the incidence of allergic contact dermatitis (ACD) to silk fibroin and 2-octyl cyanoacrylate mesh dressings after open shoulder surgery, to identify differences in clinic utilization for complications related to silk fibroin and 2-octyl cyanoacrylate mesh dressings and to collect patient reported outcome measures (PROMs) related to patient comfort and satisfaction for silk fibroin and 2-octyl cyanoacrylate mesh dressings.",[28,59],"Allergic Contact Dermatitis",[61,62,63,64,65],"silk fibroin (SYLKE)","2-octyl cyanoacrylate mesh (Dermabond PRINEO)","open shoulder surgery","hypersensitivity","contact dermatitis","NOT_YET_RECRUITING","2026-05-11",{"date":69,"type":38},"2026-05-14",{"date":71,"type":20},"2026-06-30",{"date":73,"type":20},"2028-07-30",{"name":75,"class":44},"The University of Texas Health Science Center, Houston",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100636936","post-market-safety-study-of-lumisight-100636936","NCT07572162","Post-market Safety Study of LUMISIGHT","Post-market Evaluation of Incidence Rate of Anaphylaxis and Hypersensitivity Reactions Associated With LUMISIGHT Administration","Inclusion Criteria:\n\n* 18 years of age or older\n* Has been diagnosed with primary breast cancer and scheduled to undergo a lumpectomy procedure\n* Indicated to receive LUMISIGHT at a dose of 1 mg\u002Fkg\n* Willing and able to comply with the study procedures\n\nExclusion Criteria:\n\n* History of hypersensitivity reactions to pegulicianine.\n* Inability to comply with the requirements of the protocol.\n* Treating physician does not think it is in the best interest of the patient to participate.",{"count":84,"type":20},1500,"OBSERVATIONAL","This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associated with LUMISIGHT (pegulicianine) administration in adults with breast cancer undergoing lumpectomy surgery. Participants are indicated to receive LUMISIGHT as part of their breast cancer care. There is no investigational drug associated with this study. LUMISIGHT has a risk of serious hypersensitivity reaction, and this study seeks to further evaluate that risk.",[28],[89,90,91,92,93,94,64,95,96,97],"Lumicell","LumiSystem","LUMISIGHT","Breast Cancer","Intraoperative margin detection","anaphylaxis","drug allergy","post-market safety","fluorescence guided surgery","2026-04-30",{"date":100,"type":38},"2026-05-07",{"date":102,"type":20},"2026-06",{"date":104,"type":20},"2030-12",{"name":106,"class":107},"Lumicell, Inc.","INDUSTRY"]